Evidence map›Paper›PMID 41096745›Full record

ArticleInternational journal of molecular sciences2025

FBXO22 Suppresses Oxidative Stress-Induced ASK1 Activation and Cell Death via Ubiquitination-Dependent Degradation of TRIM48.

Naoki Kashiwabara, Keita Nagaoka, Kenshin Nakajima, Hiroki Tsukamoto, Yoshihisa Tomioka, Isao Naguro, Hidenori Ichijo, Takuya Noguchi, Yusuke Hirata, Atsushi Matsuzawa

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Treatment outcomes of switching to aflibercept 8 mg in previously-treated neovascular age-related macular degeneration.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Naoki KashiwabaraLaboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Keita NagaokaLaboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Kenshin NakajimaLaboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Hiroki TsukamotoDepartment of Pharmaceutical Sciences, School of Pharmacy at Fukuoka, International University of Health and Welfare, Okawa 831-8501, Japan.ORCID 0000-0002-4585-1656
Yoshihisa TomiokaLaboratory of Oncology, Pharmacy Practice and Sciences, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.
Isao NaguroLaboratory of Bioresponse Signaling, Faculty of Pharmacy, Juntendo University, Urayasu 279-0013, Japan.ORCID 0000-0002-0338-8026
Hidenori IchijoLaboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, University of Tokyo, Bunkyo-ku, Tokyo 113-0033, Japan.
Takuya NoguchiLaboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.ORCID 0000-0001-6187-6645
Yusuke HirataLaboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.ORCID 0000-0002-1428-2075
Atsushi MatsuzawaLaboratory of Health Chemistry, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai 980-8578, Japan.ORCID 0000-0001-8303-3905

Funding

Japan Agency for Medical Research and Development (AMED) JP23ek0109685JSPS/MEXT KAKENHI JP20K07011JSPS/MEXT KAKENHI JP20KK0361JSPS/MEXT KAKENHI JP21H00268JSPS/MEXT KAKENHI JP21H02620JSPS/MEXT KAKENHI JP23K06111JSPS/MEXT KAKENHI JP24K02173JSPS/MEXT KAKENHI JP24K22011Mitsubishi Foundation not applicableResearch Grant of the Princess Takamatsu Cancer Research Fund not applicablethe Japan Foundation of Applied Enzymology not applicablethe Takeda Science Foundation not applicablethe Uehara Memorial Foundation not applicable
6 · The paper itself

Abstract

TRIM48 is a human-specific tripartite motif (TRIM) family protein with E3 ubiquitin ligase activity that plays a significant role in the oxidative stress response and tumor suppression. However, the mechanisms regulating TRIM48 expression remain unknown. In this study, we demonstrate that TRIM48 is targeted for ubiquitination-dependent degradation by S-phase kinase-associated protein 1 (Skp1)-Cullin1 (Cul1)-F-box protein (SCF) ubiquitin ligase complex, containing F-box protein 22 (FBXO22) as a substrate recognition subunit. We found that TRIM48 is a rapid turnover protein, as evidenced by the fast and drastic decrease in its protein expression level in the presence of a protein synthesis inhibitor cycloheximide, which was suppressed by knocking down either Skp1, Cul1 or FBXO22. Exogenous FBXO22 expression promoted K48-linked polyubiquitination and degradation of TRIM48. FBXO22 deficiency accelerated oxidative stress-induced activation of apoptosis signal-regulating kinase 1 (ASK1) and cell death, which was reversed by additional TRIM48 knockdown. Collectively, our findings identify the FBXO22 SCF complex as a key negative regulator of TRIM48-driven ASK1-activation and cell death under oxidative stress. The dysregulation of this axis may underlie human-specific pathologies, such as tumorigenesis and oxidative stress-associated disorders, highlighting its potential as a target for novel therapeutic interventions.

Indexed as

F-Box ProteinsMAP Kinase Kinase Kinase 5Oxidative StressUbiquitinationUbiquitin-Protein LigasesApoptosisCell DeathCullin ProteinsHEK293 CellsHumansProteolysisReceptors, Cytoplasmic and NuclearS-Phase Kinase-Associated ProteinsTripartite Motif ProteinsCullin 1Cullin ProteinsF-Box ProteinsFBXO22 protein, humanMAP3K5 protein, humanMAP Kinase Kinase Kinase 5Receptors, Cytoplasmic and NuclearS-Phase Kinase-Associated ProteinsTripartite Motif ProteinsUbiquitin-Protein LigasesASK1FBXO22oxidative stressprotein degradationTRIM48ubiquitin

Identifiers

PMID41096745
PMCPMC12524865

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.